<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28978919</article-id><article-id pub-id-type="pmc">5627278</article-id><article-id pub-id-type="publisher-id">12833</article-id><article-id pub-id-type="doi">10.1038/s41598-017-12833-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gedik</surname><given-names>Nilg&#x000fc;n</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kottenberg</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Thielmann</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Frey</surname><given-names>Ulrich H.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jakob</surname><given-names>Heinz</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Peters</surname><given-names>J&#x000fc;rgen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Heusch</surname><given-names>Gerd</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kleinbongard</surname><given-names>Petra</given-names></name><address><email>petra.kleinbongard@uk-essen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Institute for Pathophysiology, West German Heart and Vascular Center Essen, Universit&#x000e4;tsklinikum Essen, Universit&#x000e4;t Duisburg- Essen, Essen, Germany </aff><aff id="Aff2"><label>2</label>Klinik f&#x000fc;r An&#x000e4;sthesiologie und Intensivmedizin, Universit&#x000e4;tsklinikum Essen, Universit&#x000e4;t Duisburg-Essen, Essen, Germany </aff><aff id="Aff3"><label>3</label>Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center Essen, Universit&#x000e4;tsklinikum Essen, Universit&#x000e4;t Duisburg- Essen, Essen, Germany </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>4</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>7</volume><elocation-id>12660</elocation-id><history><date date-type="received"><day>11</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>15</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Remote ischemic preconditioning (RIPC) by repeated brief cycles of limb ischemia/reperfusion may reduce myocardial ischemia/reperfusion injury and improve patients&#x02018; prognosis after elective coronary artery bypass graft (CABG) surgery. The signal transducer and activator of transcription (STAT)5 activation in left ventricular myocardium is associated with RIPC&#x000b4;s cardioprotection. Cytokines and growth hormones typically activate STATs and could therefore act as humoral transfer factors of RIPC&#x000b4;s cardioprotection. We here determined arterial plasma concentrations of 25 different cytokines, growth hormones, and other factors which have previously been associated with cardioprotection, before (baseline)/after RIPC or placebo (n&#x02009;=&#x02009;23/23), respectively, and before/after ischemic cardioplegic arrest in CABG patients. RIPC-induced protection was reflected by a 35% reduction of serum troponin I release. With the exception of interleukin-1&#x003b1;, none of the humoral factors changed in their concentrations after RIPC or placebo, respectively. Interleukin-1&#x003b1;, when normalized to baseline, increased after RIPC (280&#x02009;&#x000b1;&#x02009;56%) but not with placebo (97&#x02009;&#x000b1;&#x02009;15%). The interleukin-1&#x003b1; concentration remained increased until after ischemic cardioplegic arrest and was also higher than with placebo in absolute concentrations (25&#x02009;&#x000b1;&#x02009;6 versus 16&#x02009;&#x000b1;&#x02009;3&#x02009;pg/mL). Only interleukin-1&#x003b1; possibly fulfills the criteria which would be expected from a substance to be released in response to RIPC and to protect the myocardium during ischemic cardioplegic arrest.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Remote ischemic conditioning (RIC) by brief episodes of ischemia/reperfusion in parenchymal organs or limbs before (remote ischemic preconditioning; RIPC) or during (remote ischemic perconditioning) sustained myocardial ischemia and subsequent reperfusion is a non-invasive strategy to protect the myocardium from irreversible ischemia/reperfusion injury. The protection by RIC has been demonstrated in many experimental studies and confirmed in patients undergoing elective interventional<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> or surgical coronary revascularization<sup><xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref></sup> and in patients with reperfused acute myocardial infarction<sup><xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref></sup>. The efficacy of RIC was established by a reduction in cardiac biomarker release<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup> or by cardiac imaging<sup><xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup> and resulted in improved short-term<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup> and long-term clinical outcome<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. However, two large-scaled randomized trials in patients undergoing cardiac surgery, ERICCA<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> and RIPHeart<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>, were neutral and did not confirm reduced biomarker release and improved clinical outcome with RIPC. Potential reasons for the lack of protection by RIPC in both trials relate to the use of propofol anesthesia<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup> and the inclusion of patients undergoing isolated or additional valve surgery which causes traumatic rather than ischemia/reperfusion myocardial injury and may have diluted the protection by RIPC<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. For a more successful use of RIC in patients, a better understanding of the signal transfer from the stimulus site to the heart and of RIC&#x000b4;s intracellular signal transduction is mandatory.</p><p id="Par3">In different animal models and in healthy volunteers, a neuronal and a humoral signal transfer as well as a neurohumoral interaction in signal transfer have been proposed<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>. A humoral signal transfer has been evidenced by the transfer of cardioprotection via plasma<sup><xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref></sup> or plasma-derived dialysate/filtrate<sup><xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref></sup> from one individual to another individual&#x02019;s heart, even across species. In respective experiments, several amino acids<sup><xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref></sup>, cytokines/chemokines<sup><xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref></sup>, neuropeptides<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup> as well as other substances, such as adenosine<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup>, apolipoprotein-A1 (Apo-A1)<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref></sup>, circulating RNase-1<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>, glucagon like peptide-1 (GLP-1)<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>, microRNA-144<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> and nitrite<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> have been identified and proposed as potential humoral transfer factors of RIC. Apo-A1, cytokines, circulating RNase-1, microRNA-144 and nitrite have been reported in healthy volunteers in association with the RIC procedure<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. In patients undergoing cardiac surgery, only some of the potential humoral transfer factors (amino acids, circulating RNase-1, cytokines/chemokines) have been associated with the RIC procedure<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>, but only in two studies there was also a reduction of myocardial injury by RIC<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>, and one of these studies was in infants<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>.</p><p id="Par4">Within the myocardium, the putative humoral factors activate intracellular signaling pathways, which ultimately transmit the cardioprotective signal to end-effectors, notably the mitochondria<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>. Conceptually, the intracellular signaling pathways have been categorized as the nitric oxide synthase/protein kinase G pathway, the reperfusion injury salvage kinase pathway, and the survival activating factor enhancement pathway<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>. In left ventricular biopsies of patients undergoing coronary artery bypass graft (CABG) surgery, only the phosphorylation of signal transducer and activator of transcription (STAT)5 of the survival activating factor enhancement pathway<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> was associated with cardioprotection by RIPC<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup>. STAT is typically activated by members of the cytokine and the growth hormone family<sup><xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR51">51</xref></sup>. Therefore, cytokines and growth hormones could potentially serve as humoral transfer factors of RIPC in patients.</p><p id="Par5">We have now quantified the arterial concentration of a number of humoral factors, which may potentially activate STAT and the survival activating factor enhancement pathway, in a cohort of consecutive patients undergoing CABG surgery under isoflurane anesthesia before and after RIPC/placebo, respectively, and before and after ischemic cardioplegic arrest: chemokines/cytokines, i.e. erythropoietin (EPO)<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>, interleukin-(IL-)1&#x003b1;<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>, IL-1&#x003b2;<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>, IL-2<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>, IL-6<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>, IL-8<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>, IL-10<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>, IL-15<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>, IL-17<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>, IL-33<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>, stromal cell-derived factor-1&#x003b1; (SDF-1&#x003b1;)<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>, tumor necrosis factor-&#x003b1; (TNF-&#x003b1;)<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> and growth hormones, i.e. growth hormone (GH)<sup><xref ref-type="bibr" rid="CR63">63</xref>,<xref ref-type="bibr" rid="CR64">64</xref></sup>, growth differentiation factor-11 (GDF-11)<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>, growth hormone releasing hormone (GHRH)<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>, growth hormone-releasing peptide (GHRP)<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. In addition, we determined a few other factors which have been reported before in association with cardioprotection and/or STAT activation, i.e. Apo-A1<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref></sup>, GLP-1<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>, HIF-1&#x003b1;<sup><xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR69">69</xref></sup>, leptin<sup><xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR71">71</xref></sup>, pentraxin-3<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>, prolactin<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>, RNase-1<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>, survivin<sup><xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR75">75</xref></sup> and thymosin-&#x003b2;4<sup><xref ref-type="bibr" rid="CR76">76</xref>,<xref ref-type="bibr" rid="CR77">77</xref></sup>.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Cardioprotection by RIPC</title><p id="Par6">Demographics and intraoperative characteristics were not different between patients with RIPC and placebo, respectively (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The preoperative serum troponin I (TnI) concentration did not differ between patients with RIPC and placebo, respectively. The TnI concentration area under the curve (AUC) over 72&#x02009;h was decreased by RIPC, indicating cardioprotection (190&#x02009;&#x000b1;&#x02009;16 versus 543&#x02009;&#x000b1;&#x02009;145 ng/mL&#x02009;&#x000d7;&#x02009;72&#x02009;h, p&#x02009;=&#x02009;0.015; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). In this small cohort of consecutive patients, the RIPC-related decrease in TnI release was more pronounced than that in the larger cohort reported before<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient demographics and intraoperative characteristics of patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>RIPC (n&#x02009;=&#x02009;23)</th><th>placebo (n&#x02009;=&#x02009;23)</th><th>p-value</th></tr></thead><tbody><tr><td colspan="4">
<bold>demographics</bold>
</td></tr><tr><td>age [years]</td><td>66.4&#x02009;&#x000b1;&#x02009;1.5</td><td>67.7&#x02009;&#x000b1;&#x02009;2.0</td><td>0.479</td></tr><tr><td>sex [male]</td><td>23</td><td>19</td><td>0.109</td></tr><tr><td>body weight [kg]</td><td>87.2&#x02009;&#x000b1;&#x02009;2.7</td><td>84.6&#x02009;&#x000b1;&#x02009;2.6</td><td>0.499</td></tr><tr><td colspan="4">
<bold>risk factors and co-morbidities</bold>
</td></tr><tr><td>diabetes mellitus</td><td>11</td><td>6</td><td>0.221</td></tr><tr><td>hypertension</td><td>20</td><td>22</td><td>0.608</td></tr><tr><td>hyperlipidemia</td><td>9</td><td>8</td><td>1.000</td></tr><tr><td>peripheral vessel disease</td><td>2</td><td>4</td><td>0.666</td></tr><tr><td>COPD</td><td>4</td><td>2</td><td>0.666</td></tr><tr><td>renal disease [creatinine&#x02009;&#x0003e;&#x02009;200 &#x003bc;mol/L]</td><td>1</td><td>3</td><td>0.608</td></tr><tr><td colspan="4">
<bold>cardiac status</bold>
</td></tr><tr><td>angina CCS III&#x02013;IV</td><td>1</td><td>2</td><td>1.000</td></tr><tr><td>previous myocardial infarction</td><td>2</td><td>5</td><td>0.414</td></tr><tr><td>left ventricular ejection fraction [%]</td><td>50.5&#x02009;&#x000b1;&#x02009;2.1</td><td>51.5&#x02009;&#x000b1;&#x02009;2.3</td><td>0.747</td></tr><tr><td colspan="4">
<bold>medication</bold>
</td></tr><tr><td>aspirin</td><td>23</td><td>19</td><td>0.109</td></tr><tr><td>clopidogrel</td><td>4</td><td>2</td><td>0.666</td></tr><tr><td>&#x003b2;-blockers</td><td>20</td><td>16</td><td>0.284</td></tr><tr><td>statins</td><td>17</td><td>17</td><td>1.000</td></tr><tr><td>ACE inhibitors or ARBs</td><td>8</td><td>10</td><td>0.763</td></tr><tr><td colspan="4">
<bold>risk scores</bold>
</td></tr><tr><td>additive EuroSCORE</td><td>3.9&#x02009;&#x000b1;&#x02009;0.5</td><td>5.0&#x02009;&#x000b1;&#x02009;0.6</td><td>0.174</td></tr><tr><td>logistic EuroSCORE [%]</td><td>3.4&#x02009;&#x000b1;&#x02009;0.5</td><td>5.1&#x02009;&#x000b1;&#x02009;1.0</td><td>0.109</td></tr><tr><td>EuroSCORE II [%]</td><td>1.8&#x02009;&#x000b1;&#x02009;0.2</td><td>2.8&#x02009;&#x000b1;&#x02009;0.4</td><td>0.058</td></tr><tr><td colspan="4">
<bold>intraoperative characteristics</bold>
</td></tr><tr><td>time from end of RIPC/placebo to ischemic cardioplegic arrest [min]</td><td>64.6&#x02009;&#x000b1;&#x02009;8.0</td><td>49.8&#x02009;&#x000b1;&#x02009;10.0</td><td>0.280</td></tr><tr><td>time from end of RIPC/placebo to reperfusion [min]</td><td>130.2&#x02009;&#x000b1;&#x02009;8.1</td><td>118.8&#x02009;&#x000b1;&#x02009;7.1</td><td>0.304</td></tr><tr><td>aortic cross-clamp duration [min]</td><td>70.0&#x02009;&#x000b1;&#x02009;4.8</td><td>65.4&#x02009;&#x000b1;&#x02009;3.7</td><td>0.454</td></tr><tr><td>cardioplegia [mL]</td><td>1528&#x02009;&#x000b1;&#x02009;46</td><td>1546&#x02009;&#x000b1;&#x02009;49</td><td>0.798</td></tr><tr><td>reperfusion time [min]</td><td>34.8&#x02009;&#x000b1;&#x02009;3.1</td><td>38.9&#x02009;&#x000b1;&#x02009;3.6</td><td>0.393</td></tr><tr><td>number of bypass grafts</td><td>3.7&#x02009;&#x000b1;&#x02009;0.2</td><td>3.6&#x02009;&#x000b1;&#x02009;0.2</td><td>0.752</td></tr><tr><td>transit time graft flow [mL/min]</td><td>87.7&#x02009;&#x000b1;&#x02009;12.3</td><td>66.6&#x02009;&#x000b1;&#x02009;9.9</td><td>0.204</td></tr></tbody></table><table-wrap-foot><p>Data are mean&#x02009;&#x000b1;&#x02009;standard error of the mean or number. Patient demographics and intraoperative characteristics were compared using unpaired Student&#x02019;s t-test (continuous data) and 2-tailed Fisher&#x02019;s exact test (categorical data). Chronic obstructive pulmonary disease (COPD), Canadian cardiovascular society score (CCS), angiotensin-converting enzyme (ACE), angiotensin-II-receptor blockers (ARBs), European system for cardiac operative risk evaluation (EuroSCORE), remote ischemic preconditioning (RIPC). Reperfusion time: time from release of aortic cross-clamp to end of cardiopulmonary bypass.</p></table-wrap-foot></table-wrap>
<fig id="Fig1"><label>Figure 1</label><caption><p>Serum concentration of troponin I. The serum concentration of troponin I at baseline before (preop) and over 72&#x02009;h after coronary artery bypass graft (CABG) surgery in patients undergoing remote ischemic preconditioning (RIPC; n&#x02009;=&#x02009;23, black symbols/bars) or placebo (n&#x02009;=&#x02009;23, white symbols/bars). Decreased troponin I concentrations confirmed protection by RIPC. Insert: area under the curve (AUC) for serum troponin I concentrations over 72&#x02009;h.&#x02009;<sup>+</sup>p&#x02009;&#x0003c;&#x02009;0.05 versus RIPC using 2-way ANOVA for repeated measures or unpaired Student&#x02019;s t-test (AUC).</p></caption><graphic xlink:href="41598_2017_12833_Fig1_HTML" id="d29e1048"/></fig>
</p></sec><sec id="Sec4"><title>Concentration of humoral factors</title><p id="Par7">The concentrations of the analyzed humoral factors were not significantly different between RIPC and placebo at baseline, with the exception of prolactin, which was lower with RIPC than with placebo (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). To normalize for interindividual differences, the concentrations of all factors were also normalized to their baseline.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Concentration of humoral factors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">parameter</th><th rowspan="2">protocol</th><th colspan="4">original data</th><th rowspan="2">parameter</th><th rowspan="2">protocol</th><th colspan="3">data normalized to baseline</th></tr><tr><th>baseline</th><th>after placebo/RIPC</th><th>before ischemic cardioplegic arrest</th><th>after ischemic cardioplegic arrest</th><th>after placebo/RIPC</th><th>before ischemic cardioplegic arrest</th><th>after ischemic cardioplegic arrest</th></tr></thead><tbody><tr><td rowspan="2">Apo-A1 [ng/mL]</td><td>RIPC</td><td>408&#x02009;&#x000b1;&#x02009;36</td><td>365&#x02009;&#x000b1;&#x02009;42</td><td>364&#x02009;&#x000b1;&#x02009;36</td><td>251&#x02009;&#x000b1;&#x02009;32*<sup>,#</sup>
</td><td rowspan="2">Apo-A1 [%]</td><td>RIPC</td><td>106&#x02009;&#x000b1;&#x02009;23</td><td>108&#x02009;&#x000b1;&#x02009;18</td><td>68&#x02009;&#x000b1;&#x02009;9*<sup>,#</sup>
</td></tr><tr><td>placebo</td><td>351&#x02009;&#x000b1;&#x02009;35</td><td>337&#x02009;&#x000b1;&#x02009;57</td><td>292&#x02009;&#x000b1;&#x02009;35</td><td>164&#x02009;&#x000b1;&#x02009;21*<sup>,#</sup>
</td><td>placebo</td><td>115&#x02009;&#x000b1;&#x02009;23</td><td>94&#x02009;&#x000b1;&#x02009;12</td><td>55&#x02009;&#x000b1;&#x02009;10*<sup>,#</sup>
</td></tr><tr><td rowspan="2">EPO [pg/mL]</td><td>RIPC</td><td>22&#x02009;&#x000b1;&#x02009;2</td><td>22&#x02009;&#x000b1;&#x02009;2</td><td>20&#x02009;&#x000b1;&#x02009;2</td><td>22&#x02009;&#x000b1;&#x02009;3</td><td rowspan="2">EPO [%]</td><td>RIPC</td><td>134&#x02009;&#x000b1;&#x02009;35</td><td>105&#x02009;&#x000b1;&#x02009;26</td><td>103&#x02009;&#x000b1;&#x02009;19</td></tr><tr><td>placebo</td><td>28&#x000b1;3</td><td>26&#x02009;&#x000b1;&#x02009;3</td><td>22&#x02009;&#x000b1;&#x02009;3</td><td>21&#x02009;&#x000b1;&#x02009;3</td><td>placebo</td><td>100&#x02009;&#x000b1;&#x02009;15</td><td>84&#x02009;&#x000b1;&#x02009;11</td><td>77&#x02009;&#x000b1;&#x02009;9</td></tr><tr><td rowspan="2">GDF-11 [fg/mL]</td><td>RIPC</td><td>6836&#x02009;&#x000b1;&#x02009;1544</td><td>5678&#x02009;&#x000b1;&#x02009;1031</td><td>6104&#x02009;&#x000b1;&#x02009;1174</td><td>15244&#x02009;&#x000b1;&#x02009; 2244*<sup>,#</sup>
</td><td rowspan="2">GDF-11 [%]</td><td>RIPC</td><td>99&#x02009;&#x000b1;&#x02009;17</td><td>106&#x02009;&#x000b1;&#x02009;17</td><td>275&#x02009;&#x000b1;&#x02009;54*<sup>,#</sup>
</td></tr><tr><td>placebo</td><td>5314&#x02009;&#x000b1;&#x02009;633</td><td>5960&#x02009;&#x000b1;&#x02009;771</td><td>6329&#x02009;&#x000b1;&#x02009;852</td><td>9764&#x02009;&#x000b1;&#x02009;1303*<sup>,#,+</sup>
</td><td>placebo</td><td>126&#x02009;&#x000b1;&#x02009;19</td><td>142&#x02009;&#x000b1;&#x02009;22</td><td>219&#x02009;&#x000b1;&#x02009;34*<sup>,#</sup>
</td></tr><tr><td rowspan="2">GHRH [fg/mL]</td><td>RIPC</td><td>1694&#x02009;&#x000b1;&#x02009;56</td><td>1636&#x02009;&#x000b1;&#x02009;52</td><td>1656&#x02009;&#x000b1;&#x02009;48</td><td>1621&#x02009;&#x000b1;&#x02009;59</td><td rowspan="2">GHRH [%]</td><td>RIPC</td><td>99&#x02009;&#x000b1;&#x02009;4</td><td>100&#x02009;&#x000b1;&#x02009;4</td><td>98&#x02009;&#x000b1;&#x02009;4</td></tr><tr><td>placebo</td><td>1538&#x02009;&#x000b1;&#x02009;55</td><td>1664&#x02009;&#x000b1;&#x02009;59</td><td>1699&#x02009;&#x000b1;&#x02009;54</td><td>1636&#x02009;&#x000b1;&#x02009;48</td><td>placebo</td><td>109&#x02009;&#x000b1;&#x02009;2<sup>+</sup>
</td><td>113&#x02009;&#x000b1;&#x02009;4*<sup>,+</sup>
</td><td>109&#x02009;&#x000b1;&#x02009;4*<sup>,+</sup>
</td></tr><tr><td rowspan="2">GHRP [fg/mL]</td><td>RIPC</td><td>998&#x02009;&#x000b1;&#x02009;189</td><td>1008&#x02009;&#x000b1;&#x02009;208</td><td>1220&#x02009;&#x000b1;&#x02009;236</td><td>1096&#x02009;&#x000b1;&#x02009;187</td><td rowspan="2">GHRP [%]</td><td>RIPC</td><td>275&#x02009;&#x000b1;&#x02009;180</td><td>338&#x02009;&#x000b1;&#x02009;187</td><td>123&#x02009;&#x000b1;&#x02009;18</td></tr><tr><td>placebo</td><td>1211&#x02009;&#x000b1;&#x02009;263</td><td>1147&#x02009;&#x000b1;&#x02009;240</td><td>1120&#x02009;&#x000b1;&#x02009;236</td><td>1117&#x02009;&#x000b1;&#x02009;145</td><td>placebo</td><td>120&#x02009;&#x000b1;&#x02009;16</td><td>137&#x02009;&#x000b1;&#x02009;18</td><td>225&#x02009;&#x000b1;&#x02009;37</td></tr><tr><td rowspan="2">GLP-1 [pg/mL]</td><td>RIPC</td><td>1.5&#x02009;&#x000b1;&#x02009;0.2</td><td>1.4&#x02009;&#x000b1;&#x02009;0.2</td><td>1.5&#x02009;&#x000b1;&#x02009;0.2</td><td>2.2&#x02009;&#x000b1;&#x02009;0.2*<sup>,#</sup>
</td><td rowspan="2">GLP-1 [%]</td><td>RIPC</td><td>93&#x02009;&#x000b1;&#x02009;3</td><td>103&#x02009;&#x000b1;&#x02009;7</td><td>173&#x02009;&#x000b1;&#x02009;17*<sup>,#</sup>
</td></tr><tr><td>placebo</td><td>1.5&#x02009;&#x000b1;&#x02009;0.2</td><td>1.5&#x02009;&#x000b1;&#x02009;0.2</td><td>1.6&#x02009;&#x000b1;&#x02009;0.2</td><td>2.4&#x02009;&#x000b1;&#x02009;0.2*<sup>,#</sup>
</td><td>placebo</td><td>107&#x02009;&#x000b1;&#x02009;8</td><td>122&#x02009;&#x000b1;&#x02009;16</td><td>201&#x02009;&#x000b1;&#x02009;29*<sup>,#</sup>
</td></tr><tr><td rowspan="2">GH [pg/mL]</td><td>RIPC</td><td>830&#x02009;&#x000b1;&#x02009;146</td><td>323&#x02009;&#x000b1;&#x02009;85*</td><td>221&#x02009;&#x000b1;&#x02009;44*</td><td>882&#x02009;&#x000b1;&#x02009;158<sup>#</sup>
</td><td rowspan="2">GH [%]</td><td>RIPC</td><td>60&#x02009;&#x000b1;&#x02009;19</td><td>153&#x02009;&#x000b1;&#x02009;99</td><td>500&#x02009;&#x000b1;&#x02009;327*</td></tr><tr><td>placebo</td><td>510&#x02009;&#x000b1;&#x02009;125</td><td>401&#x02009;&#x000b1;&#x02009;124</td><td>320&#x02009;&#x000b1;&#x02009;93</td><td>1059&#x02009;&#x000b1;&#x02009;270*<sup>,#</sup>
</td><td>placebo</td><td>127&#x02009;&#x000b1;&#x02009;33</td><td>305&#x02009;&#x000b1;&#x02009;116</td><td>820&#x02009;&#x000b1;&#x02009;221*<sup>,#</sup>
</td></tr><tr><td rowspan="2">HIF-1&#x003b1; [fg/mL]</td><td>RIPC</td><td>18&#x02009;&#x000b1;&#x02009;2</td><td>16&#x02009;&#x000b1;&#x02009;3</td><td>17&#x02009;&#x000b1;&#x02009;2</td><td>17&#x02009;&#x000b1;&#x02009;2</td><td rowspan="2">HIF-1&#x003b1; [%]</td><td>RIPC</td><td>101&#x02009;&#x000b1;&#x02009;20</td><td>102&#x02009;&#x000b1;&#x02009;12</td><td>101&#x02009;&#x000b1;&#x02009;10</td></tr><tr><td>placebo</td><td>19&#x02009;&#x000b1;&#x02009;3</td><td>21&#x02009;&#x000b1;&#x02009;5</td><td>20&#x02009;&#x000b1;&#x02009;5</td><td>22&#x02009;&#x000b1;&#x02009;6</td><td>placebo</td><td>133&#x02009;&#x000b1;&#x02009;17</td><td>130&#x02009;&#x000b1;&#x02009;18</td><td>159&#x02009;&#x000b1;&#x02009;33</td></tr><tr><td rowspan="2">IL-1&#x003b1; [pg/mL]</td><td>RIPC</td><td>12&#x02009;&#x000b1;&#x02009;2</td><td>20&#x02009;&#x000b1;&#x02009;2</td><td>16&#x02009;&#x000b1;&#x02009;2</td><td>25&#x02009;&#x000b1;&#x02009; 6*<sup>,#</sup>
</td><td rowspan="2">IL-1&#x003b1; [%]</td><td>RIPC</td><td>280&#x02009;&#x000b1;&#x02009;56*</td><td>235&#x02009;&#x000b1;&#x02009;96*</td><td>298&#x02009;&#x000b1;&#x02009;71*</td></tr><tr><td>placebo</td><td>18&#x02009;&#x000b1;&#x02009;3</td><td>18&#x02009;&#x000b1;&#x02009;2</td><td>15&#x02009;&#x000b1;&#x02009;3</td><td>16&#x02009;&#x000b1;&#x02009;3<sup>+</sup>
</td><td>placebo</td><td>97&#x02009;&#x000b1;&#x02009;15<sup>+</sup>
</td><td>97&#x02009;&#x000b1;&#x02009;16<sup>+</sup>
</td><td>135&#x02009;&#x000b1;&#x02009;40<sup>+</sup>
</td></tr><tr><td rowspan="2">IL-1&#x003b2; [fg/mL]</td><td>RIPC</td><td>746&#x02009;&#x000b1;&#x02009;220</td><td>734&#x02009;&#x000b1;&#x02009;210</td><td>881&#x02009;&#x000b1;&#x02009;223</td><td>1630&#x02009;&#x000b1;&#x02009;316*<sup>,#</sup>
</td><td rowspan="2">IL-1&#x003b2; [%]</td><td>RIPC</td><td>220&#x02009;&#x000b1;&#x02009;94</td><td>251&#x02009;&#x000b1;&#x02009;75</td><td>517&#x02009;&#x000b1;&#x02009;173*<sup>,#</sup>
</td></tr><tr><td>placebo</td><td>631&#x02009;&#x000b1;&#x02009;97</td><td>752&#x02009;&#x000b1;&#x02009;100</td><td>739&#x02009;&#x000b1;&#x02009;103</td><td>1367&#x02009;&#x000b1;&#x02009;222*<sup>,#</sup>
</td><td>placebo</td><td>169&#x02009;&#x000b1;&#x02009;28</td><td>178&#x02009;&#x000b1;&#x02009;46</td><td>337&#x02009;&#x000b1;&#x02009;66*</td></tr><tr><td rowspan="2">IL-2 [fg/mL]</td><td>RIPC</td><td>4936&#x02009;&#x000b1;&#x02009;440</td><td>6205&#x02009;&#x000b1;&#x02009;735</td><td>5391&#x02009;&#x000b1;&#x02009;601</td><td>5908&#x02009;&#x000b1;&#x02009;685</td><td rowspan="2">IL-2 [%]</td><td>RIPC</td><td>143&#x02009;&#x000b1;&#x02009;27</td><td>160&#x02009;&#x000b1;&#x02009;44</td><td>189&#x02009;&#x000b1;&#x02009;53*</td></tr><tr><td>placebo</td><td>7040&#x02009;&#x000b1;&#x02009;1326</td><td>7291&#x02009;&#x000b1;&#x02009;1000</td><td>5114&#x02009;&#x000b1;&#x02009;458</td><td>7351&#x02009;&#x000b1;&#x02009;1098</td><td>placebo</td><td>132&#x02009;&#x000b1;&#x02009;21</td><td>103&#x02009;&#x000b1;&#x02009;14</td><td>211&#x02009;&#x000b1;&#x02009;59*<sup>,#</sup>
</td></tr><tr><td rowspan="2">IL-6 [fg/mL]</td><td>RIPC</td><td>4108&#x02009;&#x000b1;&#x02009;715</td><td>4133&#x02009;&#x000b1;&#x02009;664</td><td>5498&#x02009;&#x000b1;&#x02009;947</td><td>14633&#x02009;&#x000b1;&#x02009;941*<sup>,#</sup>
</td><td rowspan="2">IL-6 [%]</td><td>RIPC</td><td>105&#x02009;&#x000b1;&#x02009;6</td><td>166&#x02009;&#x000b1;&#x02009;23</td><td>588&#x02009;&#x000b1;&#x02009;92*<sup>,#</sup>
</td></tr><tr><td>placebo</td><td>6239&#x02009;&#x000b1;&#x02009;882</td><td>6169&#x02009;&#x000b1;&#x02009;890</td><td>6251&#x02009;&#x000b1;&#x02009;789</td><td>16572&#x02009;&#x000b1;&#x02009;1200*<sup>,#</sup>
</td><td>placebo</td><td>99&#x02009;&#x000b1;&#x02009;2</td><td>129&#x02009;&#x000b1;&#x02009;16</td><td>439&#x02009;&#x000b1;&#x02009;85*<sup>,#,+</sup>
</td></tr><tr><td rowspan="2">IL-8 [pg/mL]</td><td>RIPC</td><td>14&#x02009;&#x000b1;&#x02009;1</td><td>14&#x02009;&#x000b1;&#x02009;1</td><td>18&#x02009;&#x000b1;&#x02009;3</td><td>59&#x02009;&#x000b1;&#x02009;12*<sup>,#</sup>
</td><td rowspan="2">IL-8 [%]</td><td>RIPC</td><td>100&#x02009;&#x000b1;&#x02009;2</td><td>125&#x02009;&#x000b1;&#x02009;22</td><td>441&#x02009;&#x000b1;&#x02009;65*<sup>,#</sup>
</td></tr><tr><td>placebo</td><td>16&#x02009;&#x000b1;&#x02009;2</td><td>15&#x02009;&#x000b1;&#x02009;2</td><td>18&#x02009;&#x000b1;&#x02009;3</td><td>49&#x02009;&#x000b1;&#x02009;9*<sup>,#,+</sup>
</td><td>placebo</td><td>100&#x02009;&#x000b1;&#x02009;4</td><td>122&#x02009;&#x000b1;&#x02009;20</td><td>367&#x02009;&#x000b1;&#x02009;42*<sup>,#</sup>
</td></tr><tr><td rowspan="2">IL-10 [fg/mL]</td><td>RIPC</td><td>3449&#x02009;&#x000b1;&#x02009;826</td><td>3943&#x02009;&#x000b1;&#x02009;1034</td><td>11320&#x02009;&#x000b1;&#x02009;5458</td><td>56674&#x02009;&#x000b1;&#x02009;1921*<sup>,#</sup>
</td><td rowspan="2">IL-10 [%]</td><td>RIPC</td><td>107&#x02009;&#x000b1;&#x02009;7</td><td>324&#x02009;&#x000b1;&#x02009;129</td><td>2227&#x02009;&#x000b1;&#x02009;792*<sup>,#</sup>
</td></tr><tr><td>placebo</td><td>2875&#x02009;&#x000b1;&#x02009;419</td><td>3096&#x02009;&#x000b1;&#x02009;487</td><td>3827&#x02009;&#x000b1;&#x02009;884</td><td>57356&#x02009;&#x000b1;&#x02009;1216*<sup>,#</sup>
</td><td>placebo</td><td>109&#x02009;&#x000b1;&#x02009;11</td><td>146&#x02009;&#x000b1;&#x02009;23</td><td>3120&#x02009;&#x000b1;&#x02009;1007*<sup>,#</sup>
</td></tr><tr><td rowspan="2">IL-15 [fg/mL]</td><td>RIPC</td><td>4380&#x02009;&#x000b1;&#x02009;280</td><td>4312&#x02009;&#x000b1;&#x02009;324</td><td>3933&#x02009;&#x000b1;&#x02009;258</td><td>4832&#x02009;&#x000b1;&#x02009;300<sup>#</sup>
</td><td rowspan="2">IL-15 [%]</td><td>RIPC</td><td>102&#x02009;&#x000b1;&#x02009;6</td><td>93&#x02009;&#x000b1;&#x02009;6</td><td>117&#x02009;&#x000b1;&#x02009;9<sup>#</sup>
</td></tr><tr><td>placebo</td><td>5253&#x02009;&#x000b1;&#x02009;690</td><td>5633&#x02009;&#x000b1;&#x02009;566</td><td>5218&#x02009;&#x000b1;&#x02009;682</td><td>6234&#x02009;&#x000b1;&#x02009;613*<sup>,#</sup>
</td><td>placebo</td><td>120&#x02009;&#x000b1;&#x02009;14</td><td>108&#x02009;&#x000b1;&#x02009;14</td><td>134&#x02009;&#x000b1;&#x02009;19*<sup>,#</sup>
</td></tr><tr><td rowspan="2">IL-17 [pg/mL]</td><td>RIPC</td><td>20&#x02009;&#x000b1;&#x02009;2</td><td>28&#x02009;&#x000b1;&#x02009;2</td><td>32&#x02009;&#x000b1;&#x02009;4*</td><td>35&#x02009;&#x000b1;&#x02009;5*</td><td rowspan="2">IL-17 [%]</td><td>RIPC</td><td>174&#x02009;&#x000b1;&#x02009;24</td><td>212&#x02009;&#x000b1;&#x02009;51*</td><td>266&#x02009;&#x000b1;&#x02009;69*</td></tr><tr><td>placebo</td><td>28&#x02009;&#x000b1;&#x02009;3</td><td>29&#x02009;&#x000b1;&#x02009;4</td><td>32&#x02009;&#x000b1;&#x02009;7</td><td>36&#x02009;&#x000b1;&#x02009;9</td><td>placebo</td><td>120&#x02009;&#x000b1;&#x02009;18</td><td>103&#x02009;&#x000b1;&#x02009;18<sup>+</sup>
</td><td>143&#x02009;&#x000b1;&#x02009;32<sup>+</sup>
</td></tr><tr><td rowspan="2">IL-33 [fg/mL]</td><td>RIPC</td><td>3997&#x02009;&#x000b1;&#x02009;544</td><td>5178&#x02009;&#x000b1;&#x02009;525</td><td>5983&#x02009;&#x000b1;&#x02009;665</td><td>19054&#x02009;&#x000b1;&#x02009;1826*<sup>,#</sup>
</td><td rowspan="2">IL-33 [%]</td><td>RIPC</td><td>146&#x02009;&#x000b1;&#x02009;15</td><td>178&#x02009;&#x000b1;&#x02009;23</td><td>615&#x02009;&#x000b1;&#x02009;92*<sup>,#</sup>
</td></tr><tr><td>placebo</td><td>3679&#x02009;&#x000b1;&#x02009;530</td><td>5454&#x02009;&#x000b1;&#x02009;675</td><td>7059&#x02009;&#x000b1;&#x02009;1587*</td><td>21732&#x02009;&#x000b1;&#x02009;1888*<sup>,#</sup>
</td><td>placebo</td><td>153&#x02009;&#x000b1;&#x02009;13</td><td>190&#x02009;&#x000b1;&#x02009;40</td><td>633&#x02009;&#x000b1;&#x02009;72*<sup>,#</sup>
</td></tr><tr><td rowspan="2">leptin [pg/mL]</td><td>RIPC</td><td>56&#x02009;&#x000b1;&#x02009;9</td><td>49&#x02009;&#x000b1;&#x02009;9</td><td>43&#x02009;&#x000b1;&#x02009;8</td><td>40&#x02009;&#x000b1;&#x02009;1</td><td rowspan="2">leptin [%]</td><td>RIPC</td><td>88&#x02009;&#x000b1;&#x02009;3*</td><td>74&#x02009;&#x000b1;&#x02009;3*</td><td>67&#x02009;&#x000b1;&#x02009;3*<sup>,#</sup>
</td></tr><tr><td>placebo</td><td>73&#x02009;&#x000b1;&#x02009;23</td><td>65&#x02009;&#x000b1;&#x02009;23</td><td>50&#x02009;&#x000b1;&#x02009;11*</td><td>48&#x02009;&#x000b1;&#x02009;8*</td><td>placebo</td><td>86&#x02009;&#x000b1;&#x02009;3*</td><td>77&#x02009;&#x000b1;&#x02009;3*</td><td>72&#x02009;&#x000b1;&#x02009;4*</td></tr><tr><td rowspan="2">pentraxin-3 [pg/mL]</td><td>RIPC</td><td>804&#x02009;&#x000b1;&#x02009;137</td><td>808&#x02009;&#x000b1;&#x02009;129</td><td>1002&#x02009;&#x000b1;&#x02009;1211</td><td>3453&#x02009;&#x000b1;&#x02009;281*<sup>,#</sup>
</td><td rowspan="2">pentraxin-3 [%]</td><td>RIPC</td><td>106&#x02009;&#x000b1;&#x02009;4</td><td>160&#x02009;&#x000b1;&#x02009;16</td><td>697&#x02009;&#x000b1;&#x02009;104*<sup>,#</sup>
</td></tr><tr><td>placebo</td><td>1061&#x02009;&#x000b1;&#x02009;204</td><td>982&#x02009;&#x000b1;&#x02009;160</td><td>1240&#x02009;&#x000b1;&#x02009;162</td><td>4745&#x02009;&#x000b1;&#x02009;831*<sup>,#,+</sup>
</td><td>placebo</td><td>99&#x02009;&#x000b1;&#x02009;5</td><td>159&#x02009;&#x000b1;&#x02009;23</td><td>928&#x02009;&#x000b1;&#x02009;239*<sup>,#</sup>
</td></tr><tr><td rowspan="2">prolactin [ng/mL]</td><td>RIPC</td><td>34&#x02009;&#x000b1;&#x02009;3</td><td>44&#x02009;&#x000b1;&#x02009;4</td><td>52&#x02009;&#x000b1;&#x02009;5*</td><td>58&#x02009;&#x000b1;&#x02009;7*</td><td rowspan="2">prolactin [%]</td><td>RIPC</td><td>158&#x02009;&#x000b1;&#x02009;31</td><td>208&#x02009;&#x000b1;&#x02009;56*</td><td>233&#x02009;&#x000b1;&#x02009;51*</td></tr><tr><td>placebo</td><td>48&#x02009;&#x000b1;&#x02009;4<sup>+</sup>
</td><td>60&#x02009;&#x000b1;&#x02009;6<sup>+</sup>
</td><td>61&#x02009;&#x000b1;&#x02009;7</td><td>52&#x02009;&#x000b1;&#x02009;7</td><td>placebo</td><td>138&#x02009;&#x000b1;&#x02009;30</td><td>143&#x02009;&#x000b1;&#x02009;35</td><td>119&#x02009;&#x000b1;&#x02009;29<sup>+</sup>
</td></tr><tr><td rowspan="2">RNase-1 [pg/mL]</td><td>RIPC</td><td>663&#x02009;&#x000b1;&#x02009;150</td><td>464&#x02009;&#x000b1;&#x02009;94</td><td>728&#x02009;&#x000b1;&#x02009;100</td><td>1744&#x02009;&#x000b1;&#x02009;120*<sup>,#</sup>
</td><td rowspan="2">RNase-1 [%]</td><td>RIPC</td><td>93&#x02009;&#x000b1;&#x02009;10</td><td>200&#x02009;&#x000b1;&#x02009;37</td><td>405&#x02009;&#x000b1;&#x02009;69*<sup>,#</sup>
</td></tr><tr><td>placebo</td><td>477&#x02009;&#x000b1;&#x02009;37</td><td>460&#x02009;&#x000b1;&#x02009;82</td><td>795&#x02009;&#x000b1;&#x02009;94*</td><td>1627&#x02009;&#x000b1;&#x02009;241*<sup>,#</sup>
</td><td>placebo</td><td>131&#x02009;&#x000b1;&#x02009;20</td><td>244&#x02009;&#x000b1;&#x02009;33*</td><td>519&#x02009;&#x000b1;&#x02009;96*<sup>,#</sup>
</td></tr><tr><td rowspan="2">SDF-1&#x003b1; [pg/mL]</td><td>RIPC</td><td>2270&#x02009;&#x000b1;&#x02009;94</td><td>2197&#x02009;&#x000b1;&#x02009;99</td><td>2766&#x02009;&#x000b1;&#x02009;126*</td><td>2846&#x02009;&#x000b1;&#x02009;98*</td><td rowspan="2">SDF-1&#x003b1; [%]</td><td>RIPC</td><td>97&#x02009;&#x000b1;&#x02009;1</td><td>123&#x02009;&#x000b1;&#x02009;4*</td><td>127&#x02009;&#x000b1;&#x02009;3*</td></tr><tr><td>placebo</td><td>2382&#x02009;&#x000b1;&#x02009;102</td><td>2327&#x02009;&#x000b1;&#x02009;97</td><td>2881&#x02009;&#x000b1;&#x02009;105*</td><td>2922&#x02009;&#x000b1;&#x02009;120*</td><td>placebo</td><td>98&#x02009;&#x000b1;&#x02009;2</td><td>124&#x02009;&#x000b1;&#x02009;5*</td><td>126&#x02009;&#x000b1;&#x02009;5*</td></tr><tr><td rowspan="2">surviving [pg/mL]</td><td>RIPC</td><td>36&#x02009;&#x000b1;&#x02009;9</td><td>46&#x02009;&#x000b1;&#x02009;7</td><td>34&#x02009;&#x000b1;&#x02009;3</td><td>58&#x02009;&#x000b1;&#x02009;1</td><td rowspan="2">surviving [%]</td><td>RIPC</td><td>227&#x02009;&#x000b1;&#x02009;51</td><td>152&#x02009;&#x000b1;&#x02009;25</td><td>313&#x02009;&#x000b1;&#x02009;57</td></tr><tr><td>placebo</td><td>45&#x02009;&#x000b1;&#x02009;7</td><td>56&#x02009;&#x000b1;&#x02009;9</td><td>51&#x02009;&#x000b1;&#x02009;8</td><td>90&#x02009;&#x000b1;&#x02009;8*<sup>,#,+</sup>
</td><td>placebo</td><td>151&#x02009;&#x000b1;&#x02009;28</td><td>193&#x02009;&#x000b1;&#x02009;56</td><td>472&#x02009;&#x000b1;&#x02009;277*<sup>,#</sup>
</td></tr><tr><td rowspan="2">thymosin-&#x003b2;4 [ng/mL]</td><td>RIPC</td><td>349&#x02009;&#x000b1;&#x02009;29</td><td>322&#x02009;&#x000b1;&#x02009;25</td><td>285&#x02009;&#x000b1;&#x02009;22</td><td>280&#x02009;&#x000b1;&#x02009;31</td><td rowspan="2">thymosin-&#x003b2;4 [%]</td><td>RIPC</td><td>96&#x02009;&#x000b1;&#x02009;4</td><td>90&#x02009;&#x000b1;&#x02009;7</td><td>99&#x02009;&#x000b1;&#x02009;15</td></tr><tr><td>placebo</td><td>364&#x02009;&#x000b1;&#x02009;46</td><td>371&#x02009;&#x000b1;&#x02009;39</td><td>362&#x02009;&#x000b1;&#x02009;42</td><td>316&#x02009;&#x000b1;&#x02009;27</td><td>placebo</td><td>110&#x02009;&#x000b1;&#x02009;9</td><td>109&#x02009;&#x000b1;&#x02009;8</td><td>105&#x02009;&#x000b1;&#x02009;11</td></tr><tr><td rowspan="2">TNF-&#x003b1; [fg/mL]</td><td>RIPC</td><td>2973&#x02009;&#x000b1;&#x02009;744</td><td>3107&#x02009;&#x000b1;&#x02009;737</td><td>3259&#x02009;&#x000b1;&#x02009;800</td><td>4301&#x02009;&#x000b1;&#x02009;744*<sup>,#</sup>
</td><td rowspan="2">TNF-&#x003b1; [%]</td><td>RIPC</td><td>108&#x02009;&#x000b1;&#x02009;3</td><td>116&#x02009;&#x000b1;&#x02009;6</td><td>198&#x02009;&#x000b1;&#x02009;42*<sup>,#</sup>
</td></tr><tr><td>placebo</td><td>2892&#x02009;&#x000b1;&#x02009;580</td><td>3105&#x02009;&#x000b1;&#x02009;566</td><td>2772&#x02009;&#x000b1;&#x02009;265</td><td>3827&#x02009;&#x000b1;&#x02009;450*<sup>,#</sup>
</td><td>placebo</td><td>111&#x02009;&#x000b1;&#x02009;3</td><td>116&#x02009;&#x000b1;&#x02009;7</td><td>166&#x02009;&#x000b1;&#x02009;19*<sup>,#</sup>
</td></tr></tbody></table><table-wrap-foot><p>Data are mean&#x02009;&#x02009;&#x000b1;&#x02009;&#x02009;standard error of the mean. Concentrations of all humoral factors were analyzed by 2-way (group, time) ANOVA for repeated measures followed by Fisher&#x02019;s post hoc tests. *p&#x02009;&#x0003c;&#x02009;0.05 versus baseline, <sup>#</sup>p&#x02009;&#x0003c;&#x02009;0.05 versus before ischemic cardioplegic arrest, <sup>+</sup>p&#x02009;&#x0003c;&#x02009;0.05 versus RIPC. Apolipoprotein A1 (Apo-A1), erythropoietin (EPO), growth differentiation factor-11 (GDF-11), growth hormone (GH), growth hormone-releasing peptide (GHRP), glucagon like peptide-1 (GLP-1), hypoxia inducible factor 1&#x003b1; (HIF-1&#x003b1;), interleukin (IL), remote ischemic preconditioning (RIPC), ribonuclease A (RNase-1), stromal cell derived factor-1 &#x003b1; (SDF-1&#x003b1;), tumor necrosis factor-&#x003b1; (TNF-&#x003b1;).</p></table-wrap-foot></table-wrap>
</p><p id="Par8">The concentrations (normalized and not normalized to baseline) of Apo-A1, EPO, GHRP, GLP-1, GH, HIF-1&#x003b1;, IL-1&#x003b2;, IL-2, IL-10, IL-15, IL-33, leptin, RNase-1, SDF-1&#x003b1;, thymosin-&#x003b2;4 and TNF-&#x003b1; did not differ between RIPC and placebo at all analyzed time points (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The concentration of Apo-A1 decreased, whereas the concentrations of GLP-1, GH, IL-1&#x003b2;, IL-10, IL-15, IL-33, RNase-1, SDF-1&#x003b1; and TNF-&#x003b1; increased after ischemic cardioplegic arrest over that at baseline and before ischemic cardioplegic arrest (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par9">The IL-1&#x003b1; concentration, when normalized to baseline, increased after the RIPC procedure and remained increased until after ischemic cardioplegic arrest, whereas it was unchanged with placebo. In absolute concentrations, interleukin-1&#x003b1; increased after ischemic cardioplegic arrest over that at baseline and before ischemic cardioplegic arrest with RIPC, whereas it did not change over time with placebo (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>Plasma concentration of interleukin-1&#x003b1;. The plasma concentration of interleukin-1&#x003b1; (IL-1&#x003b1;) before (baseline) and after remote ischemic preconditioning (RIPC; n&#x02009;=&#x02009;23, black bars) or the placebo protocol (n&#x02009;=&#x02009;23, white bars) and before and after ischemic cardioplegic arrest, respectively, in patients undergoing coronary artery bypass graft surgery. The plasma concentration of IL-1&#x003b1; was increased after ischemic cardioplegic arrest with RIPC and was greater with RIPC than with placebo (<bold>a</bold>). After normalization to baseline, the IL-1&#x003b1; plasma concentration was greater with RIPC than with placebo throughout the remaining protocol (<bold>b</bold>). *p&#x02009;&#x0003c;&#x02009;0.05 versus baseline, <sup>#</sup>p&#x02009;&#x0003c;&#x02009;0.05 versus before ischemic cardioplegic arrest, <sup>+</sup>p&#x02009;&#x0003c;&#x02009;0.05 versus RIPC using 2-way ANOVA for repeated measures, followed by Fisher&#x02019;s post hoc tests.</p></caption><graphic xlink:href="41598_2017_12833_Fig2_HTML" id="d29e2922"/></fig>
</p><p id="Par10">The concentrations of GDF-11 and IL-8 increased after ischemic cardioplegic arrest and were greater with RIPC than with placebo, but after normalization to baseline these changes were no longer significant (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The concentrations of pentraxin-3 and survivin increased after ischemic cardioplegic arrest and were lower with RIPC than with placebo, but again after normalization to baseline these changes were no longer significant (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par11">Exclusively after normalization to baseline, the GHRH concentration was lower with RIPC than with placebo throughout the remaining protocol. The normalized concentrations of IL-6 and prolactin were greater with RIPC than with placebo after ischemic cardioplegic arrest. The normalized concentration of IL-17 was greater with RIPC than with placebo before and after ischemic cardioplegic arrest (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p></sec></sec><sec id="Sec5" sec-type="discussion"><title>Discussion</title><p id="Par12">Except for IL-1&#x003b1;, none of the analyzed humoral factors in our study appeared to fulfill the criteria for a transfer factor of cardioprotection by RIC (increase in the factor&#x02019;s concentration after the RIC procedure and before myocardial ischemia as well as association with reduced myocardial ischemia/reperfusion injury), and we thus add another mostly negative study to the so far elusive search for RIC&#x000b4;s transfer factor<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Our study was unique in that it was conducted in patients undergoing CABG surgery, where the RIPC procedure indeed induced cardioprotection. However, none of the humoral factors differed in absolute concentration between RIPC and placebo before ischemic cardioplegic arrest. The concentrations of some factors (GDF-11, GHRH, IL-1&#x003b1;, IL-6, IL-8 and IL-17) were greater with RIPC than with placebo after ischemic cardioplegic arrest. For these factors, however, it is unclear whether this difference is truly related to myocardial ischemia/reperfusion injury and protection from it. Cardiopulmonary bypass inflicts a systemic inflammatory injury to the entire body and induces damage to various parenchymal organs<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>. RIC, in turn, is also a systemic response and provides protection to a number of parenchymal organs<sup><xref ref-type="bibr" rid="CR79">79</xref>,<xref ref-type="bibr" rid="CR80">80</xref></sup>. Therefore, the observed differences in the concentrations of the above humoral factors may originate from other organs than the heart.</p><p id="Par13">The IL-1&#x003b1; concentration, when normalized to baseline, was increased after the RIPC procedure and it remained increased until after ischemic cardioplegic arrest whereas it was not changed throughout the placebo protocol. In absolute concentrations, IL-1&#x003b1; was also greater with RIPC than with placebo after ischemic cardioplegic arrest. IL-1&#x003b1; is a member of the IL-1 cytokine family and involved in inflammatory processes. IL-1&#x003b1; is released from macrophages, monocytes, endothelial and epithelial cells<sup><xref ref-type="bibr" rid="CR81">81</xref>,<xref ref-type="bibr" rid="CR82">82</xref></sup> but also from cardiomyocytes<sup><xref ref-type="bibr" rid="CR83">83</xref></sup> in response to cell injury. In mice with myocardial infarction, IL-1&#x003b1; was released into the systemic circulation, whereas IL-1&#x003b1; in the myocardial tissue did not change<sup><xref ref-type="bibr" rid="CR83">83</xref></sup>. In isolated perfused rat hearts, IL-1&#x003b1; blockade after reperfusion reduced infarct size<sup><xref ref-type="bibr" rid="CR84">84</xref></sup>, suggesting that intracellular IL-1&#x003b1; contributes to ischemia/reperfusion injury. However, exogenous IL-1&#x003b1; preconditioning<sup><xref ref-type="bibr" rid="CR85">85</xref></sup> and pretreatment<sup><xref ref-type="bibr" rid="CR86">86</xref></sup> in isolated perfused rat hearts improved ventricular systolic pressure and reduced infarct size, suggesting that circulating, extracellular IL-1&#x003b1; induces cardioprotection. A causal role of IL-1&#x003b1; as humoral mediator and trigger for intracellular signaling in RIC remains to be established. Whereas IL-1&#x003b2; is known to activate STATs<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>, the exact role of IL-1&#x003b1; in STAT activation is not clear so far. IL-1&#x003b1; could indirectly activate STATs by induction of IL-6<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. Except for IL-1&#x003b1;, which has not been associated with RIC before, we could not confirm any of the previously reported humoral factors to be associated with cardioprotection by RIC.</p><p id="Par14">There are limitations of our current study: 1) Given our small patient cohort and the high number of analyzed humoral factors, the risk of a type I error with respect to IL-1&#x003b1; is high, in particular since its increase after the RIPC procedure was only evident with normalized data. Our exploratory study is hypothesis generating, so replication in a larger cohort of patients is mandatory. 2) We used plasma samples from a consecutive patient cohort with co-morbidities and co-medications, some of which may potentially interfere with the protection by ischemic conditioning maneuvers<sup><xref ref-type="bibr" rid="CR87">87</xref>&#x02013;<xref ref-type="bibr" rid="CR89">89</xref></sup>, but also with the release of humoral factors. Patients undergoing RIPC were younger and had lower preoperative risk scores than those undergoing the placebo procedure, and these differences may have contributed to the more pronounced decrease in TnI release than that in the larger cohort reported before<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. 3) We analyzed the plasma concentrations only at four defined time points, i.e. before/5&#x02009;min after the RIPC/placebo protocol and before/10&#x02009;min after ischemic cardioplegic arrest, not considering for the potentially different kinetics of each humoral factor. In particular, the time from the end of the RIPC/placebo procedure to ischemic cardioplegic arrest was a bit longer in patients with RIPC than with placebo, and we may have missed a transient increase or decrease in humoral factors with RIPC.</p></sec><sec id="Sec6" sec-type="materials|methods"><title>Methods</title><sec id="Sec7"><title>Ethics Statement</title><p id="Par15">The study conforms to the principles of the Declaration of Helsinki. With approval by the local ethics committee (Institutional Review Board, University of Duisburg-Essen, no. 08&#x02013;3683) and patients&#x02019; written informed consent, arterial blood samples were harvested from a small cohort of consecutive patients (n&#x02009;=&#x02009;23 RIPC/23 placebo) who underwent elective isolated first-time CABG surgery<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. These patients were enrolled between February 2012 and April 2013 and within the framework of a larger, randomized, prospective, double-blind, placebo-controlled trial (ClinicalTrials.gov NCT01406678, date of registration: December 1, 2009). The inclusion and exclusion criteria for the trial as well as its results have been reported<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p></sec><sec id="Sec8"><title>Study procedure</title><p id="Par16">Anesthesia was induced with sufentanil (1&#x02009;&#x000b5;g/kg), etomidate (0.3&#x02009;mg/kg) and rocuronium (0.6&#x02009;mg/kg) and maintained with isoflurane (0.6&#x02013;1.0% end-tidal). The RIPC protocol consisted of 3 cycles of 5&#x02009;min left upper arm ischemia/5&#x02009;min reperfusion, and data were compared to placebo (cuff left deflated for 30&#x02009;min). CABG was performed using median sternotomy, mild systemic hypothermia (&#x0003e;32&#x02009;&#x000b0;C) and antegrade cold crystalloid Bretschneider (K&#x000f6;hler Chemie GmbH, Bensheim, Germany) cardioplegia, with additional topical cooling and single aortic cross-clamping for all distal anastomoses<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p></sec><sec id="Sec9"><title>Arterial blood samples and plasma preparation</title><p id="Par17">Arterial blood samples were taken before (baseline) and 5&#x02009;min after the end of the RIPC/placebo procedure as well as before and 10&#x02009;min after the ischemic cardioplegic arrest. These time points were chosen to detect changes induced by the RIPC protocol per se and the interaction of RIPC with ischemic cardioplegic arrest. At each time point, 25&#x02009;mL arterial blood was withdrawn and sampled in vials containing lithium-heparin (Sarstedt, N&#x000fc;mbrecht, Germany). The arterial blood was then immediately centrifuged at 4&#x02009;&#x000b0;C with 800&#x02009;g for 15&#x02009;min, plasma was separated, stored at &#x02212;80&#x02009;&#x000b0;C for later use and again centrifuged for 10&#x02009;min at 4500&#x02009;g before use. Additionally, 5&#x02009;mL of arterial blood was withdrawn in separate vials (Sarstedt, N&#x000fc;mbrecht, Germany) to analyze the serum concentration of prolactin.</p></sec><sec id="Sec10"><title>Serum troponin I</title><p id="Par18">Venous blood samples were withdrawn from each patient on the day before surgery and postoperatively at 1, 6, 12, 24, 48, and 72&#x02009;h. Serum TnI concentration was measured using a specific two-side immunoassay with the DimensionR RxL MaxR integrated system (Dimension Flex, Dade Behring GmbH, Marburg, Germany) in the central laboratory of the University Duisburg-Essen Medical School. The detection range of TnI was 0.04 to 40&#x02009;&#x000b5;g/L, the upper limit of normal 0.1&#x02009;&#x000b5;g/L. The AUC for serum TnI concentration was calculated according to the trapezoidal rule. Missing values were replaced by linear inter- and extrapolation<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p></sec><sec id="Sec11"><title>Plasma concentrations of humoral factors</title><p id="Par19">The plasma concentrations of humoral factors were determined using enzyme immunoassays. Standards and samples were added to microplates, which were precoated with the specific antibody against the respective protein.</p><p id="Par20">For the detection of Apo-A1<sup><xref ref-type="bibr" rid="CR90">90</xref></sup>, EPO<sup><xref ref-type="bibr" rid="CR91">91</xref></sup>, GDF-11<sup><xref ref-type="bibr" rid="CR92">92</xref></sup>, RNase-1<sup><xref ref-type="bibr" rid="CR93">93</xref></sup> (ELISA Cloud-Immunoassay, Houston, USA) and HIF-1&#x003b1;<sup><xref ref-type="bibr" rid="CR94">94</xref></sup> (RayBio, Georgia, USA) avidin-conjugated horseradish peroxidase was supplemented. For the detection of GLP-1<sup><xref ref-type="bibr" rid="CR95">95</xref></sup> (Abcam, Cambridge, UK) an antibody cocktail consisting of a capture and a detector antibody was supplemented. For the detection of GH<sup><xref ref-type="bibr" rid="CR96">96</xref></sup>, IL-1&#x003b1;<sup><xref ref-type="bibr" rid="CR97">97</xref></sup>, IL-2<sup><xref ref-type="bibr" rid="CR98">98</xref></sup>, IL-15<sup><xref ref-type="bibr" rid="CR99">99</xref></sup>, IL-17<sup><xref ref-type="bibr" rid="CR99">99</xref></sup>, IL-33<sup><xref ref-type="bibr" rid="CR100">100</xref></sup>, leptin<sup><xref ref-type="bibr" rid="CR101">101</xref></sup>, pentraxin-3<sup><xref ref-type="bibr" rid="CR102">102</xref></sup>, SDF-1&#x003b1;<sup><xref ref-type="bibr" rid="CR103">103</xref></sup> and survivin<sup><xref ref-type="bibr" rid="CR104">104</xref></sup> (R&#x00026;D systems, Abingdon, UK) an enzyme-linked polyclonal horseradish peroxidase-conjugated antibody was supplemented. For the detection of GHRH<sup><xref ref-type="bibr" rid="CR105">105</xref></sup> and GHRP<sup><xref ref-type="bibr" rid="CR106">106</xref></sup> (ELISA Cloud-Immunoassay, Houston, USA) biotin-conjugated antibodies against the respective protein were added to the microplate, and the antibodies on the plate and the biotin-labeled antibodies then competed for each other. An avidin-conjugated horseradish peroxidase-conjugated secondary antibody was supplemented. For the detection of thymosin-&#x003b2;4<sup><xref ref-type="bibr" rid="CR107">107</xref></sup> (Immundiagnostik, Bensheim, Germany) an antibody against thymosin-&#x003b2;4 was added to the microplate, which was precoated with the immobilized antigen to thymosin-&#x003b2;4. The antigen of the sample and the immobilized antigen then competed for each other. A horseradish peroxidase-conjugated secondary antibody was supplemented.</p><p id="Par21">After adding the respective substrate, the enzyme-substrate reaction resulted in a blue product. The color intensity was proportional to the concentration of the protein. The reaction was stopped, and the color changed to yellow. The color intensity was measured at 450&#x02009;nm using a spectrophotometer (Microplate Reader 680, BIORAD, M&#x000fc;nchen, Germany).</p><p id="Par22">For the detection of IL-1&#x003b2;<sup><xref ref-type="bibr" rid="CR97">97</xref></sup>, IL-6<sup><xref ref-type="bibr" rid="CR108">108</xref></sup>, IL-8<sup><xref ref-type="bibr" rid="CR108">108</xref></sup>, IL-10<sup><xref ref-type="bibr" rid="CR98">98</xref></sup> and TNF-&#x003b1;<sup><xref ref-type="bibr" rid="CR108">108</xref></sup> (R&#x00026;D systems, Abingdon, UK) an enzyme-linked polyclonal antibody and a substrate solution were supplemented. After adding an amplifier enzyme the enzyme-substrate reaction resulted in a violet product. The color intensity was proportional to the enzyme activity, which was related to the concentration of bound proteins. The reaction was stopped, and the color intensity was measured at 490&#x02009;nm using a spectrophotometer (Microplate Reader 680, BIORAD, M&#x000fc;nchen, Germany).</p><p id="Par23">The prolactin concentration was measured in the central laboratory of the University Duisburg-Essen Medical School. The detection range of prolactin assay was 0.3&#x02009;&#x003bc;g/L to 200&#x02009;&#x003bc;g/L. The serum concentration of prolactin was measured using a two-side sandwich chemiluminescence immunoassay with an acridinium ester-conjugated antibody against prolactin and a secondary antibody covalently coupled to paramagnetic particles (ADVIAR Centaur XP, Siemens, Tarrytown, USA)<sup><xref ref-type="bibr" rid="CR109">109</xref></sup>.</p><p id="Par24">The concentrations of the respective proteins were quantified by comparison to a standard curve.</p></sec><sec id="Sec12"><title>Statistics</title><p id="Par25">Data are expressed as mean&#x02009;&#x000b1;&#x02009;standard error of the mean (SEM). Statistics were performed using SigmaStat software (SigmaStat 2.03, SPSS Inc., Chicago, IL, USA). Patient demographics and intraoperative characteristics were compared using unpaired Student&#x02019;s t-test (continuous data) and 2-tailed Fisher&#x02019;s exact test (categorical data). Serum TnI of patients was analyzed by 2-way (group, time) ANOVA for repeated measures. The AUC for the serum TnI over 72&#x02009;h was compared between RIPC and placebo by unpaired Student&#x02019;s t-test. Plasma concentrations of all humoral factors were analyzed by 2-way (group, time) ANOVA for repeated measures. When a significant difference was detected, ANOVA was followed by Fisher&#x02019;s post hoc tests. Differences were considered significant at the level of p&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec></body><back><fn-group><fn><p>
<bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>G.H. was supported by the German Research Foundation (He 1320/18&#x02013;3; SFB 1116 B08), the Hans und Gertie Fischer Foundation, the Dr. Deichmann Foundation and the EU (COST Action CA16225). P.K. was supported by the German Research Foundation (SFB 1116 B08).</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>N.G. and P.K. conceived and designed the experiments. N.G. and P.K. performed the experiments. M.T., E.K., U.F., J.P. and H.J. performed the clinical study. N.G. and P.K. analyzed the data. P.K. contributed reagents/materials/analysis tools. N.G. and P.K. wrote the paper. GH designed the original study and finalized the paper. All authors reviewed the manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar1"><title>Competing Interests</title><p id="Par26">The authors declare that they have no competing interests.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>WR</given-names></name><etal/></person-group><article-title>Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: The CRISP stent trial long-term follow-up</article-title><source>Circ Cardiovasc Interv.</source><year>2013</year><volume>6</volume><fpage>246</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.112.000184</pub-id><pub-id pub-id-type="pmid">23696599</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial</article-title><source>Lancet.</source><year>2007</year><volume>370</volume><fpage>575</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)61296-3</pub-id><pub-id pub-id-type="pmid">17707752</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thielmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial</article-title><source>Lancet.</source><year>2013</year><volume>382</volume><fpage>597</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)61450-6</pub-id><pub-id pub-id-type="pmid">23953384</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Candilio</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: a randomised controlled clinical trial</article-title><source>Heart.</source><year>2015</year><volume>10</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2014-306178</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nouraei</surname><given-names>SM</given-names></name><name><surname>Baradari</surname><given-names>AG</given-names></name><name><surname>Jazayeri</surname><given-names>A</given-names></name></person-group><article-title>Does remote ischaemic preconditioning protect kidney and cardiomyocytes after coronary revascularization? A double blind controlled clinical trial</article-title><source>Med Arch.</source><year>2016</year><volume>70</volume><fpage>373</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.5455/medarh.2016.70.373-378</pub-id><pub-id pub-id-type="pmid">27994300</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f8;tker</surname><given-names>HE</given-names></name><etal/></person-group><article-title>Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial</article-title><source>Lancet.</source><year>2010</year><volume>375</volume><fpage>727</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)62001-8</pub-id><pub-id pub-id-type="pmid">20189026</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eitel</surname><given-names>I</given-names></name><etal/></person-group><article-title>Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial</article-title><source>Eur Heart J.</source><year>2015</year><volume>36</volume><fpage>3049</fpage><lpage>3057</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv463</pub-id><pub-id pub-id-type="pmid">26385956</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction</article-title><source>J Am Coll Cardiol Cardiovasc Interv.</source><year>2015</year><volume>8</volume><fpage>178</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.jcin.2014.05.015</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yellon</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Remote ischemic conditioning reduces myocardial infarct size in STEMI patients treated by thrombolysis</article-title><source>J Am Coll Cardiol.</source><year>2015</year><volume>65</volume><fpage>2764</fpage><lpage>2765</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2015.02.082</pub-id><pub-id pub-id-type="pmid">26112203</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Hong</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name></person-group><article-title>Remote ischaemic preconditioning reduces myocardial ischaemic reperfusion injury in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention</article-title><source>Acta Cardiol.</source><year>2016</year><volume>71</volume><fpage>596</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1080/AC.71.5.3167504</pub-id><pub-id pub-id-type="pmid">27695018</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sloth</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention</article-title><source>Eur Heart J.</source><year>2014</year><volume>35</volume><fpage>168</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/eht369</pub-id><pub-id pub-id-type="pmid">24031025</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Remote ischemic preconditioning and outcomes of cardiac surgery</article-title><source>N Engl J Med.</source><year>2015</year><volume>373</volume><fpage>1408</fpage><lpage>1417</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1413534</pub-id><pub-id pub-id-type="pmid">26436207</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meybohm</surname><given-names>P</given-names></name><etal/></person-group><article-title>A multicenter trial of remote ischemic preconditioning for heart surgery</article-title><source>N Engl J Med.</source><year>2015</year><volume>373</volume><fpage>1397</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1413579</pub-id><pub-id pub-id-type="pmid">26436208</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kottenberg</surname><given-names>E</given-names></name><etal/></person-group><article-title>Protection by remote ischaemic preconditioning during coronary artery bypass grafting with isoflurane but not with propofol anesthesia - a clinical trial</article-title><source>Acta Anaesthesiol Scand.</source><year>2012</year><volume>56</volume><fpage>30</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1111/j.1399-6576.2011.02585.x</pub-id><pub-id pub-id-type="pmid">22103808</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>G</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name></person-group><article-title>ERICCA and RIPHeart: two nails in the coffin for cardioprotection by remote ischemic conditioning? Probably not!</article-title><source>Eur Heart J.</source><year>2016</year><volume>37</volume><fpage>200</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv606</pub-id><pub-id pub-id-type="pmid">26508160</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>G</given-names></name><name><surname>Rassaf</surname><given-names>T</given-names></name></person-group><article-title>Time to give op on cardioprotection? A critical appraisal of clinical studies on ischemic pre-, post-, and remote conditioning</article-title><source>Circ Res.</source><year>2016</year><volume>119</volume><fpage>676</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.308736</pub-id><pub-id pub-id-type="pmid">27539973</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>G</given-names></name></person-group><article-title>Remote ischemic conditioning: the enigmatic transfer of protection</article-title><source>Cardiovasc Res.</source><year>2017</year><volume>113</volume><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvw240</pub-id><pub-id pub-id-type="pmid">28069695</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinbongard</surname><given-names>P</given-names></name><name><surname>Skyschally</surname><given-names>A</given-names></name><name><surname>Heusch</surname><given-names>G</given-names></name></person-group><article-title>Cardioprotection by remote ischemic conditioning and its signal transduction</article-title><source>Pflugers Arch.</source><year>2017</year><volume>469</volume><fpage>159</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1007/s00424-016-1922-6</pub-id><pub-id pub-id-type="pmid">27928644</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>EW</given-names></name><etal/></person-group><article-title>Rabbit heart can be &#x0201c;preconditioned&#x0201d; via transfer of coronary effluent</article-title><source>Am J Physiol.</source><year>1999</year><volume>277</volume><fpage>H2451</fpage><lpage>H2457</lpage><pub-id pub-id-type="pmid">10600868</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection</article-title><source>Clin Sci (Lond).</source><year>2009</year><volume>117</volume><fpage>191</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1042/CS20080523</pub-id><pub-id pub-id-type="pmid">19175358</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skyschally</surname><given-names>A</given-names></name><etal/></person-group><article-title>Across-species transfer of protection by remote ischemic preconditioning with species-specific myocardial signal transduction by reperfusion injury salvage kinase and survival activating factor enhancement pathways</article-title><source>Circ Res.</source><year>2015</year><volume>117</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.306878</pub-id><pub-id pub-id-type="pmid">26058828</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gedik</surname><given-names>N</given-names></name><etal/></person-group><article-title>Cardiomyocyte mitochondria as targets of humoral factors released by remote ischemic preconditioning</article-title><source>Arch Med Sci.</source><year>2016</year><volume>13</volume><fpage>448</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">28261301</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>RV</given-names></name><name><surname>Stottrup</surname><given-names>NB</given-names></name><name><surname>Kristiansen</surname><given-names>SB</given-names></name><name><surname>B&#x000f8;tker</surname><given-names>HE</given-names></name></person-group><article-title>Release of a humoral circulating cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural pathways in diabetic patients</article-title><source>Basic Res Cardiol.</source><year>2012</year><volume>107</volume><fpage>285</fpage><pub-id pub-id-type="doi">10.1007/s00395-012-0285-1</pub-id><pub-id pub-id-type="pmid">22821347</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rassaf</surname><given-names>T</given-names></name><etal/></person-group><article-title>Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning</article-title><source>Circ Res.</source><year>2014</year><volume>114</volume><fpage>1601</fpage><lpage>1610</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.303822</pub-id><pub-id pub-id-type="pmid">24643960</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hildebrandt</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Kinetics and signal activation properties of circulating factor(s) from healthy volunteers undergoing remote ischemic pre-conditioning</article-title><source>JACC Basic Transl Sci.</source><year>2016</year><volume>1</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.jacbts.2016.01.007</pub-id><pub-id pub-id-type="pmid">27642642</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Chao de la Barca, J. M. <italic>et al</italic>. Metabolic signature of remote ischemic preconditioning involving a cocktail of amino acids and biogenic amines. <italic>J Am Heart Assoc</italic>. <bold>5</bold> (2016).</mixed-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olenchock</surname><given-names>BA</given-names></name><etal/></person-group><article-title>EGLN1 inhibition and rerouting of alpha-ketoglutarate suffice for remote ischemic protection</article-title><source>Cell.</source><year>2016</year><volume>164</volume><fpage>884</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.02.006</pub-id><pub-id pub-id-type="pmid">26919427</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jose Alburquerque-Bejar</surname><given-names>J</given-names></name><etal/></person-group><article-title>Remote ischemic conditioning provides humoural cross-species cardioprotection through glycine receptor activation</article-title><source>Cardiovasc Res.</source><year>2017</year><volume>113</volume><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvw242</pub-id><pub-id pub-id-type="pmid">28069702</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouassi Nzoughet</surname><given-names>J</given-names></name><etal/></person-group><article-title>A nontargeted UHPLC-HRMS metabolomics pipeline for metabolite identification: Application to cardiac remote ischemic preconditioning</article-title><source>Anal Chem.</source><year>2017</year><volume>89</volume><fpage>2138</fpage><lpage>2146</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.6b04912</pub-id><pub-id pub-id-type="pmid">27992159</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><etal/></person-group><article-title>Limb ischemic preconditioning reduces heart and lung injury after an open heart operation in infants</article-title><source>Pediatr Cardiol.</source><year>2010</year><volume>31</volume><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1007/s00246-009-9536-9</pub-id><pub-id pub-id-type="pmid">19787388</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albrecht</surname><given-names>M</given-names></name><etal/></person-group><article-title>Remote ischemic preconditioning regulates HIF-1alpha levels, apoptosis and inflammation in heart tissue of cardiosurgical patients: a pilot experimental study</article-title><source>Basic Res Cardiol.</source><year>2013</year><volume>108</volume><fpage>314</fpage><pub-id pub-id-type="doi">10.1007/s00395-012-0314-0</pub-id><pub-id pub-id-type="pmid">23203207</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Remote ischaemic preconditioning involves signalling through the SDF-1alpha/CXCR4 signalling axis</article-title><source>Basic Res Cardiol.</source><year>2013</year><volume>108</volume><fpage>377</fpage><pub-id pub-id-type="doi">10.1007/s00395-013-0377-6</pub-id><pub-id pub-id-type="pmid">23917520</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oba</surname><given-names>T</given-names></name><etal/></person-group><article-title>Renal nerve-mediated erythropoietin release confers cardioprotection during remote ischemic preconditioning</article-title><source>Circ J.</source><year>2015</year><volume>79</volume><fpage>1557</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-14-1171</pub-id><pub-id pub-id-type="pmid">25833080</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>SZ</given-names></name><etal/></person-group><article-title>Kappa-opioid receptors mediate cardioprotection by remote preconditioning</article-title><source>Anesthesiology.</source><year>2006</year><volume>105</volume><fpage>550</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1097/00000542-200609000-00019</pub-id><pub-id pub-id-type="pmid">16931988</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name></person-group><article-title>TRPV1 activation is involved in the cardioprotection of remote limb ischemic postconditioning in ischemia-reperfusion injury rats</article-title><source>Biochem Biophys Res Commun.</source><year>2015</year><volume>463</volume><fpage>1034</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2015.06.054</pub-id><pub-id pub-id-type="pmid">26079883</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liem</surname><given-names>DA</given-names></name><name><surname>Verdouw</surname><given-names>PD</given-names></name><name><surname>Ploeg</surname><given-names>H</given-names></name><name><surname>Kazim</surname><given-names>S</given-names></name><name><surname>Duncker</surname><given-names>D</given-names></name></person-group><article-title>Sites of action of adenosine in interorgan preconditioning of the heart</article-title><source>Am J Physiol Heart Circ Physiol.</source><year>2002</year><volume>283</volume><fpage>H29</fpage><lpage>H37</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.01031.2001</pub-id><pub-id pub-id-type="pmid">12063271</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Remote cardioprotection by transfer of coronary effluent from ischemic preconditioned rabbit heart preserves mitochondrial integrity and function via adenosine receptor activation</article-title><source>Cardiovasc Drugs Ther.</source><year>2014</year><volume>28</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1007/s10557-013-6489-2</pub-id><pub-id pub-id-type="pmid">24018748</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hepponstall</surname><given-names>M</given-names></name><etal/></person-group><article-title>Remote ischemic preconditioning (RIPC) modifies plasma proteome in humans</article-title><source>PLoS One.</source><year>2012</year><volume>7</volume><fpage>e48284</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0048284</pub-id><pub-id pub-id-type="pmid">23139772</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hibert</surname><given-names>P</given-names></name><etal/></person-group><article-title>Apolipoprotein A-I is a potential mediator of remote ischemic preconditioning</article-title><source>PLoS One.</source><year>2013</year><volume>8</volume><fpage>e77211</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0077211</pub-id><pub-id pub-id-type="pmid">24155931</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Cabrera-Fuentes, H. A. <italic>et al</italic>. RNase1 as a potential mediator of remote ischaemic preconditioning for cardioprotection. <italic>Eur J Cardiothorac Surg</italic>. <bold>48</bold>, 732&#x02013;737; discussion 737 (2015).</mixed-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basalay</surname><given-names>M</given-names></name><etal/></person-group><article-title>Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning</article-title><source>Cardiovasc Res.</source><year>2016</year><volume>112</volume><fpage>669</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvw216</pub-id><pub-id pub-id-type="pmid">27702763</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>MicroRNA-144 is a circulating effector of remote ischemic preconditioning</article-title><source>Basic Res Cardiol.</source><year>2014</year><volume>109</volume><fpage>423</fpage><pub-id pub-id-type="doi">10.1007/s00395-014-0423-z</pub-id><pub-id pub-id-type="pmid">25060662</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downey</surname><given-names>JM</given-names></name><name><surname>Krieg</surname><given-names>T</given-names></name><name><surname>Cohen</surname><given-names>MV</given-names></name></person-group><article-title>Mapping preconditioning&#x02019;s signaling pathways: an engineering approach</article-title><source>Ann N Y Acad Sci.</source><year>2008</year><volume>1123</volume><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1196/annals.1420.022</pub-id><pub-id pub-id-type="pmid">18375591</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>G</given-names></name></person-group><article-title>Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning</article-title><source>Circ Res.</source><year>2015</year><volume>116</volume><fpage>674</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.305348</pub-id><pub-id pub-id-type="pmid">25677517</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>G</given-names></name><name><surname>Boengler</surname><given-names>K</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name></person-group><article-title>Cardioprotection: nitric oxide, protein kinases, and mitochondria</article-title><source>Circulation.</source><year>2008</year><volume>118</volume><fpage>1915</fpage><lpage>1919</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.805242</pub-id><pub-id pub-id-type="pmid">18981312</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinbongard</surname><given-names>P</given-names></name><name><surname>Heusch</surname><given-names>G</given-names></name></person-group><article-title>Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection?</article-title><source>Br J Pharmacol.</source><year>2015</year><volume>172</volume><fpage>2010</fpage><lpage>2025</lpage><pub-id pub-id-type="doi">10.1111/bph.12902</pub-id><pub-id pub-id-type="pmid">25204973</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecour</surname><given-names>S</given-names></name></person-group><article-title>Activation of the protective survivor activating factor enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK path?</article-title><source>J Mol Cell Cardiol.</source><year>2009</year><volume>47</volume><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2009.03.019</pub-id><pub-id pub-id-type="pmid">19344728</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>G</given-names></name><etal/></person-group><article-title>STAT5 activation and cardioprotection by remote ischemic preconditioning in humans</article-title><source>Circ Res.</source><year>2012</year><volume>110</volume><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.259556</pub-id><pub-id pub-id-type="pmid">22116817</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gedik</surname><given-names>N</given-names></name><etal/></person-group><article-title>No evidence for activated autophagy in left ventricular myocardium at early reperfusion with protection by remote ischemic preconditioning in patients undergoing coronary artery bypass grafting</article-title><source>PLoS One.</source><year>2014</year><volume>9</volume><fpage>e96567</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0096567</pub-id><pub-id pub-id-type="pmid">24797938</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boengler</surname><given-names>K</given-names></name><name><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name><name><surname>Drexler</surname><given-names>H</given-names></name><name><surname>Heusch</surname><given-names>G</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name></person-group><article-title>The myocardial JAK/STAT pathway: from protection to failure</article-title><source>Pharmacol Ther.</source><year>2008</year><volume>120</volume><fpage>172</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2008.08.002</pub-id><pub-id pub-id-type="pmid">18786563</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haghikia</surname><given-names>A</given-names></name><name><surname>Stapel</surname><given-names>B</given-names></name><name><surname>Hoch</surname><given-names>M</given-names></name><name><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name></person-group><article-title>STAT3 and cardiac remodeling</article-title><source>Heart Fail Rev.</source><year>2011</year><volume>16</volume><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1007/s10741-010-9170-x</pub-id><pub-id pub-id-type="pmid">20407820</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piuhola</surname><given-names>J</given-names></name><etal/></person-group><article-title>Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury</article-title><source>Clin Sci (Lond).</source><year>2008</year><volume>114</volume><fpage>293</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1042/CS20070229</pub-id><pub-id pub-id-type="pmid">17919123</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libert</surname><given-names>C</given-names></name><name><surname>Brouckaert</surname><given-names>P</given-names></name><name><surname>Shaw</surname><given-names>A</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name></person-group><article-title>Induction of interleukin 6 by human and murine recombinant interleukin 1 in mice</article-title><source>Eur J Immunol.</source><year>1990</year><volume>20</volume><fpage>691</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1002/eji.1830200333</pub-id><pub-id pub-id-type="pmid">2318254</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morton</surname><given-names>NM</given-names></name><name><surname>de Groot</surname><given-names>RP</given-names></name><name><surname>Cawthorne</surname><given-names>MA</given-names></name><name><surname>Emilsson</surname><given-names>V</given-names></name></person-group><article-title>Interleukin-1beta activates a short STAT-3 isoform in clonal insulin-secreting cells</article-title><source>FEBS Lett.</source><year>1999</year><volume>442</volume><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(98)01623-8</pub-id><pub-id pub-id-type="pmid">9923604</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JX</given-names></name><etal/></person-group><article-title>The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15</article-title><source>Immunity.</source><year>1995</year><volume>2</volume><fpage>331</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/1074-7613(95)90141-8</pub-id><pub-id pub-id-type="pmid">7719938</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawn</surname><given-names>B</given-names></name><etal/></person-group><article-title>Il-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2</article-title><source>Cardiovasc Res.</source><year>2004</year><volume>64</volume><fpage>61</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2004.05.011</pub-id><pub-id pub-id-type="pmid">15364614</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gharavi</surname><given-names>NM</given-names></name><etal/></person-group><article-title>Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids <italic>in vitro</italic> and in atherosclerosis <italic>in vivo</italic></article-title><source>J Biol Chem.</source><year>2007</year><volume>282</volume><fpage>31460</fpage><lpage>31468</lpage><pub-id pub-id-type="doi">10.1074/jbc.M704267200</pub-id><pub-id pub-id-type="pmid">17726017</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manukyan</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Interleukin-10 protects the ischemic heart from reperfusion injury via the STAT3 pathway</article-title><source>Surgery.</source><year>2011</year><volume>150</volume><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2011.05.017</pub-id><pub-id pub-id-type="pmid">21719057</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Interleukin-17A mediates cardiomyocyte apoptosis through Stat3-iNOS pathway</article-title><source>Biochim Biophys Acta.</source><year>2016</year><volume>1863</volume><fpage>2784</fpage><lpage>2794</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.08.013</pub-id><pub-id pub-id-type="pmid">27566322</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruisong</surname><given-names>M</given-names></name><etal/></person-group><article-title>The protective role of interleukin-33 in myocardial ischemia and reperfusion is associated with decreased HMGB1 expression and up-regulation of the p38 MAPK signaling pathway</article-title><source>PLoS One.</source><year>2015</year><volume>10</volume><fpage>e0143064</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0143064</pub-id><pub-id pub-id-type="pmid">26571038</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><etal/></person-group><article-title>SDF-1/CXCR4 mediates acute protection of cardiac function through myocardial STAT3 signaling following global ischemia/reperfusion injury</article-title><source>Am J Physiol Heart Circ Physiol.</source><year>2011</year><volume>301</volume><fpage>H1496</fpage><lpage>H1505</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00365.2011</pub-id><pub-id pub-id-type="pmid">21821779</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacerda</surname><given-names>L</given-names></name><name><surname>Somers</surname><given-names>S</given-names></name><name><surname>Opie</surname><given-names>LH</given-names></name><name><surname>Lecour</surname><given-names>S</given-names></name></person-group><article-title>Ischemic postconditioning protects against reperfusion injury via the SAFE pathway</article-title><source>Cardiovasc Res.</source><year>2009</year><volume>84</volume><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvp274</pub-id><pub-id pub-id-type="pmid">19666677</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ram</surname><given-names>PA</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Choi</surname><given-names>HK</given-names></name><name><surname>Waxman</surname><given-names>DJ</given-names></name></person-group><article-title>Growth hormone activation of Stat 1, Stat 3, and Stat 5 in rat liver. Differential kinetics of hormone desensitization and growth hormone stimulation of both tyrosine phosphorylation and serine/threonine phosphorylation</article-title><source>J Biol Chem.</source><year>1996</year><volume>271</volume><fpage>5929</fpage><lpage>5940</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.10.5929</pub-id><pub-id pub-id-type="pmid">8621467</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>MJ</given-names></name><name><surname>Brooks</surname><given-names>AJ</given-names></name></person-group><article-title>JAK2 activation by growth hormone and other cytokines</article-title><source>Biochem J.</source><year>2015</year><volume>466</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1042/BJ20141293</pub-id><pub-id pub-id-type="pmid">25656053</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loffredo</surname><given-names>FS</given-names></name><etal/></person-group><article-title>Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy</article-title><source>Cell.</source><year>2013</year><volume>153</volume><fpage>828</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.04.015</pub-id><pub-id pub-id-type="pmid">23663781</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penna</surname><given-names>C</given-names></name><etal/></person-group><article-title>GH-releasing hormone induces cardioprotection in isolated male rat heart via activation of RISK and SAFE pathways</article-title><source>Endocrinology.</source><year>2013</year><volume>154</volume><fpage>1624</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.1210/en.2012-2064</pub-id><pub-id pub-id-type="pmid">23417421</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>S</given-names></name></person-group><article-title>Multiple signaling pathways mediate ghrelin-induced proliferation of hippocampal neural stem cells</article-title><source>J Endocrinol.</source><year>2013</year><volume>218</volume><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1530/JOE-13-0045</pub-id><pub-id pub-id-type="pmid">23608221</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>H</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><article-title>Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart</article-title><source>Proc Natl Acad Sci USA</source><year>2013</year><volume>110</volume><fpage>17462</fpage><lpage>17467</lpage><pub-id pub-id-type="doi">10.1073/pnas.1317158110</pub-id><pub-id pub-id-type="pmid">24101519</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>G</given-names></name></person-group><article-title>HIF-1alpha and paradoxical phenomena in cardioprotection</article-title><source>Cardiovasc Res.</source><year>2012</year><volume>96</volume><fpage>214</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvs145</pub-id><pub-id pub-id-type="pmid">22822099</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>G</given-names></name></person-group><article-title>Obesity&#x02013;a risk factor or a RISK factor for myocardial infarction?</article-title><source>Br.J Pharmacol.</source><year>2006</year><volume>149</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706833</pub-id><pub-id pub-id-type="pmid">16894350</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore</article-title><source>Am J Physiol Heart Circ Physiol.</source><year>2010</year><volume>299</volume><fpage>H1265</fpage><lpage>H1270</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00092.2010</pub-id><pub-id pub-id-type="pmid">20656889</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction</article-title><source>Circulation.</source><year>2008</year><volume>117</volume><fpage>1055</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.749234</pub-id><pub-id pub-id-type="pmid">18268142</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Prolactin protects cardiomyocytes against intermittent hypoxia-induced cell damage by the modulation of signaling pathways related to cardiac hypertrophy and proliferation</article-title><source>Int J Cardiol.</source><year>2015</year><volume>181</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2014.11.154</pub-id><pub-id pub-id-type="pmid">25531577</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levkau</surname><given-names>B</given-names></name><etal/></person-group><article-title>Survivin determines cardiac function by controlling total cardiomyocyte number</article-title><source>Circulation.</source><year>2008</year><volume>117</volume><fpage>1583</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.734160</pub-id><pub-id pub-id-type="pmid">18332262</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>R</given-names></name><etal/></person-group><article-title>Survivin: a novel player in insulin cardioprotection against myocardial ischemia/reperfusion injury</article-title><source>J Mol Cell Cardiol.</source><year>2011</year><volume>50</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2010.08.017</pub-id><pub-id pub-id-type="pmid">20801129</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinkel</surname><given-names>R</given-names></name><etal/></person-group><article-title>Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection</article-title><source>Circulation.</source><year>2008</year><volume>117</volume><fpage>2232</fpage><lpage>2240</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.758904</pub-id><pub-id pub-id-type="pmid">18427126</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>W</given-names></name><etal/></person-group><article-title>Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury</article-title><source>Front Pharmacol.</source><year>2013</year><volume>4</volume><fpage>149</fpage><pub-id pub-id-type="doi">10.3389/fphar.2013.00149</pub-id><pub-id pub-id-type="pmid">24348421</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lok</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Smith</surname><given-names>JA</given-names></name></person-group><article-title>Understanding noncardiac complications following coronary artery bypass graft surgery</article-title><source>Clin Pract.</source><year>2014</year><volume>11</volume><fpage>193</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.2217/cpr.14.1</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Candilio</surname><given-names>L</given-names></name><name><surname>Malik</surname><given-names>A</given-names></name><name><surname>Hausenloy</surname><given-names>DJ</given-names></name></person-group><article-title>Protection of organs other than the heart by remote ischemic conditioning</article-title><source>J Cardiovasc Med (Hagerstown.).</source><year>2013</year><volume>14</volume><fpage>193</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.2459/JCM.0b013e328359dd7b</pub-id><pub-id pub-id-type="pmid">23079610</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarbock</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial</article-title><source>JAMA.</source><year>2015</year><volume>313</volume><fpage>2133</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.4189</pub-id><pub-id pub-id-type="pmid">26024502</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rider</surname><given-names>P</given-names></name><name><surname>Carmi</surname><given-names>Y</given-names></name><name><surname>Voronov</surname><given-names>E</given-names></name><name><surname>Apte</surname><given-names>RN</given-names></name></person-group><article-title>Interleukin-1alpha</article-title><source>Semin Immunol.</source><year>2013</year><volume>25</volume><fpage>430</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2013.10.005</pub-id><pub-id pub-id-type="pmid">24183701</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borthwick</surname><given-names>LA</given-names></name></person-group><article-title>The IL-1 cytokine family and its role in inflammation and fibrosis in the lung</article-title><source>Semin Immunopathol.</source><year>2016</year><volume>38</volume><fpage>517</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1007/s00281-016-0559-z</pub-id><pub-id pub-id-type="pmid">27001429</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lugrin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cutting edge: IL-1alpha is a crucial danger signal triggering acute myocardial inflammation during myocardial infarction</article-title><source>J Immunol.</source><year>2015</year><volume>194</volume><fpage>499</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1401948</pub-id><pub-id pub-id-type="pmid">25505286</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauro</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Reduction of myocardial ischemia-reperfusion injury by inhibiting interleukin-1 alpha</article-title><source>J Cardiovasc Pharmacol.</source><year>2017</year><volume>69</volume><fpage>156</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1097/FJC.0000000000000452</pub-id><pub-id pub-id-type="pmid">28267688</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maulik</surname><given-names>N</given-names></name><etal/></person-group><article-title>Interleukin-1a preconditioning reduces myocardial ischemia reperfusion injury</article-title><source>Circulation.</source><year>1993</year><volume>88</volume><fpage>387</fpage><lpage>394</lpage></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogae</surname><given-names>C</given-names></name><etal/></person-group><article-title>Interleukin 1 alpha-induced expression of manganous superoxide dismutase reduces myocardial reperfusion injury in the rat</article-title><source>J Mol Cell Cardiol.</source><year>1995</year><volume>27</volume><fpage>2091</fpage><lpage>2099</lpage><pub-id pub-id-type="doi">10.1016/S0022-2828(95)91155-3</pub-id><pub-id pub-id-type="pmid">8576926</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferdinandy</surname><given-names>P</given-names></name><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Heusch</surname><given-names>G</given-names></name><name><surname>Baxter</surname><given-names>GF</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name></person-group><article-title>Interaction of risk factors, comorbidities and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning</article-title><source>Pharmacol Rev.</source><year>2014</year><volume>66</volume><fpage>1142</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1124/pr.113.008300</pub-id><pub-id pub-id-type="pmid">25261534</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>ZV</given-names></name><etal/></person-group><article-title>Functional genomics of cardioprotection by ischemic conditioning and the influence of comorbid conditions: implications in target identification</article-title><source>Curr Drug Targets.</source><year>2015</year><volume>16</volume><fpage>904</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.2174/1389450116666150427154203</pub-id><pub-id pub-id-type="pmid">25915487</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreadou</surname><given-names>I</given-names></name><etal/></person-group><article-title>Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning</article-title><source>Br J Pharmacol.</source><year>2017</year><volume>174</volume><fpage>1555</fpage><lpage>1569</lpage><pub-id pub-id-type="doi">10.1111/bph.13704</pub-id><pub-id pub-id-type="pmid">28060997</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X</given-names></name><etal/></person-group><article-title>The association of a distinct plasma proteomic profile with the cervical high-grade squamous intraepithelial lesion of Uyghur women: a 2D liquid-phase chromatography/mass spectrometry study</article-title><source>Biomarkers.</source><year>2012</year><volume>17</volume><fpage>352</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.3109/1354750X.2012.673133</pub-id><pub-id pub-id-type="pmid">22458349</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciniselli</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone</article-title><source>Expert Rev Proteomics.</source><year>2015</year><volume>12</volume><fpage>695</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1586/14789450.2015.1099436</pub-id><pub-id pub-id-type="pmid">26496240</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><etal/></person-group><article-title>GDF11 is increased in patients with myelodysplastic syndrome</article-title><source>Int J Clin Exp Pathol.</source><year>2016</year><volume>9</volume><fpage>6031</fpage><lpage>6038</lpage></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>L</given-names></name><etal/></person-group><article-title>The human host defense ribonucleases 1, 3 and 7 are elevated in patients with sepsis after major surgery: A pilot study</article-title><source>Int J Mol Sci.</source><year>2016</year><volume>17</volume><fpage>294</fpage><pub-id pub-id-type="doi">10.3390/ijms17030294</pub-id><pub-id pub-id-type="pmid">26927088</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><etal/></person-group><article-title>The relationship between serum hypoxia-inducible factor 1alpha and coronary artery calcification in asymptomatic type 2 diabetic patients</article-title><source>Cardiovasc Diabetol.</source><year>2014</year><volume>13</volume><fpage>52</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-13-52</pub-id><pub-id pub-id-type="pmid">24564828</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Uncoupling protein 2 negatively regulates glucose-induced glucagon-like peptide 1 secretion</article-title><source>J Mol Endocrinol.</source><year>2012</year><volume>48</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1530/JME-11-0114</pub-id><pub-id pub-id-type="pmid">22257551</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betts</surname><given-names>JA</given-names></name><name><surname>Beelen</surname><given-names>M</given-names></name><name><surname>Stokes</surname><given-names>KA</given-names></name><name><surname>Saris</surname><given-names>WH</given-names></name><name><surname>van Loon</surname><given-names>LJ</given-names></name></person-group><article-title>Endocrine responses during overnight recovery from exercise: impact of nutrition and relationships with muscle protein synthesis</article-title><source>Int J Sport Nutr Exerc Metab.</source><year>2011</year><volume>21</volume><fpage>398</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1123/ijsnem.21.5.398</pub-id><pub-id pub-id-type="pmid">21832304</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vambutas</surname><given-names>A</given-names></name><etal/></person-group><article-title>Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease</article-title><source>J Clin Invest.</source><year>2014</year><volume>124</volume><fpage>4115</fpage><lpage>4122</lpage><pub-id pub-id-type="doi">10.1172/JCI76503</pub-id><pub-id pub-id-type="pmid">25133431</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadeghi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy</article-title><source>AIDS Res Hum Retroviruses.</source><year>2007</year><volume>23</volume><fpage>886</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1089/aid.2006.0228</pub-id><pub-id pub-id-type="pmid">17678471</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>MM</given-names></name><etal/></person-group><article-title>The systemic cytokine environment is permanently altered in multiple myeloma</article-title><source>PLoS One.</source><year>2013</year><volume>8</volume><fpage>e58504</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0058504</pub-id><pub-id pub-id-type="pmid">23544044</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Carotid plaque and bone density and microarchitecture in psoriatic arthritis: the correlation with soluble ST2</article-title><source>Sci Rep.</source><year>2016</year><volume>6</volume><fpage>32116</fpage><pub-id pub-id-type="doi">10.1038/srep32116</pub-id><pub-id pub-id-type="pmid">27554830</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A dietary supplement containing cinnamon, chromium and carnosine decreases fasting plasma glucose and increases lean mass in overweight or obese pre-diabetic subjects: A randomized, placebo-controlled trial</article-title><source>PLoS One.</source><year>2015</year><volume>10</volume><fpage>e0138646</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0138646</pub-id><pub-id pub-id-type="pmid">26406981</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Chemerin and adiponectin contribute reciprocally to metabolic syndrome</article-title><source>PLoS One.</source><year>2012</year><volume>7</volume><fpage>e34710</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0034710</pub-id><pub-id pub-id-type="pmid">22509348</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dei Cas</surname><given-names>A</given-names></name><etal/></person-group><article-title>Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes</article-title><source>Cardiovasc Diabetol.</source><year>2017</year><volume>16</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1186/s12933-017-0503-0</pub-id><pub-id pub-id-type="pmid">28231835</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer</article-title><source>PLoS One.</source><year>2012</year><volume>7</volume><fpage>e46737</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0046737</pub-id><pub-id pub-id-type="pmid">23091600</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarasiuk</surname><given-names>A</given-names></name><name><surname>Berdugo-Boura</surname><given-names>N</given-names></name><name><surname>Troib</surname><given-names>A</given-names></name><name><surname>Segev</surname><given-names>Y</given-names></name></person-group><article-title>Role of growth hormone-releasing hormone in sleep and growth impairments induced by upper airway obstruction in rats</article-title><source>Eur Respir J.</source><year>2011</year><volume>38</volume><fpage>870</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1183/09031936.00197610</pub-id><pub-id pub-id-type="pmid">21406516</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>BB</given-names></name><etal/></person-group><article-title>Expression of ghrelin in human salivary glands and its levels in saliva and serum in Chinese obese children and adolescents</article-title><source>Arch Oral Biol.</source><year>2011</year><volume>56</volume><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/j.archoralbio.2010.10.014</pub-id><pub-id pub-id-type="pmid">21075359</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smart</surname><given-names>N</given-names></name><name><surname>Dube</surname><given-names>KN</given-names></name><name><surname>Riley</surname><given-names>PR</given-names></name></person-group><article-title>Identification of thymosin beta4 as an effector of Hand1-mediated vascular development</article-title><source>Nat Commun.</source><year>2010</year><volume>1</volume><fpage>46</fpage><pub-id pub-id-type="doi">10.1038/ncomms1041</pub-id><pub-id pub-id-type="pmid">20975697</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teichert</surname><given-names>T</given-names></name><etal/></person-group><article-title>Association between traffic-related air pollution, subclinical inflammation and impaired glucose metabolism: results from the SALIA study</article-title><source>PLoS One.</source><year>2013</year><volume>8</volume><fpage>e83042</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0083042</pub-id><pub-id pub-id-type="pmid">24340078</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuring</surname><given-names>AN</given-names></name><name><surname>Kelsch</surname><given-names>R</given-names></name><name><surname>Pierscinski</surname><given-names>G</given-names></name><name><surname>Nofer</surname><given-names>JR</given-names></name></person-group><article-title>Establishing reference intervals for sex hormones on the analytical platforms Advia Centaur and Immulite 2000XP</article-title><source>Ann Lab Med.</source><year>2016</year><volume>36</volume><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.3343/alm.2016.36.1.55</pub-id><pub-id pub-id-type="pmid">26522760</pub-id></element-citation></ref></ref-list></back></article>